大剂量免疫抑制联合自体造血干细胞移植治疗复发缓解型多发性硬化
HALT-MS为II期临床试验,评估大剂量免疫抑制联合自体造血干细胞移植(HDIT/HCT)对复发缓解型多发性硬化(RRMS)的疗效与安全性。24例接受移植,中位随访62个月,无事件生存率69.2%,无进展生存率91.3%,无临床复发生存率86.9%,无MRI活动生存率86.3%。结论认为HDIT/HCT无需维持治疗即可诱导5年持续缓解。
要点
- HDIT/HCT后5年无事件生存率69.2%,无进展生存率91.3%。
- 无临床复发生存率86.9%,无MRI活动生存率86.3%。
- 毒性符合预期,未观察到显著晚期神经不良效应。
核心结论
- HDIT/HCT无需维持治疗即可在5年内有效诱导活动性RRMS的长期持续缓解。
研究设计与样本
- HALT-MS为II期临床试验,纳入在接受疾病修饰治疗期间仍出现复发伴残疾进展(EDSS 3.0-5.5)的RRMS患者。
- 主要终点为无事件生存(EFS),即无死亡、残疾进展、复发或MRI新发病灶。
主要发现
- EFS为69.2%(90%CI 50.2-82.1)。
- 无进展生存为91.3%(90%CI 74.7%-97.2%)。
- 无临床复发生存为86.9%(90%CI 69.5%-94.7%)。
- 无MRI活动生存为86.3%(90%CI 68.1%-94.5%)。
- 存活并完成研究者的EDSS中位变化为-0.5(四分位距-1.5至0.0;p=0.001)。
关键数值与推荐
- HDIT/HCT相关不良事件符合预期毒性,未报告显著晚期神经不良效应。
临床怎么用
- 对于疾病修饰治疗下仍活动伴残疾进展的RRMS患者,HDIT/HCT可考虑为诱导长期缓解的治疗选择。
局限性
- 本研究为II期临床试验,样本量较小(24例接受移植),证据等级为Class IV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety, efficacy, and durability of multiple sclerosis (MS) disease stabilization after high-dose immunosuppressive therapy (HDIT) and autologous hematopoietic cell transplantation (HCT). METHODS: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT-MS) is a phase II clinical trial of HDIT/HCT for patients with relapsing-remitting (RR) MS who experienced relapses with disability progression (Expanded Disability Status Scale [EDSS] 3.0-5.5) while on MS disease-modifying therapy. The primary endpoint was event-free survival (EFS), defined as survival without death or disease activity from any one of: disability progression, relapse, or new lesions on MRI. Participants were evaluated through 5 years posttransplant. Toxicities were reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (AE). RESULTS: Twenty-five participants were evaluated for transplant and 24 participants underwent HDIT/HCT. Median follow-up was 62 months (range 12-72). EFS was 69.2% (90% confidence interval [CI] 50.2-82.1). Progression-free survival, clinical relapse-free survival, and MRI activity-free survival were 91.3% (90% CI 74.7%-97.2%), 86.9% (90% CI 69.5%-94.7%), and 86.3% (90% CI 68.1%-94.5%), respectively. AE due to HDIT/HCT were consistent with expected toxicities and there were no significant late neurologic adverse effects noted. Improvements were noted in neurologic disability with a median change in EDSS of -0.5 (interquartile range -1.5 to 0.0; p = 0.001) among participants who survived and completed the study. CONCLUSION: HDIT/HCT without maintenance therapy was effective for inducing long-term sustained remissions of active RRMS at 5 years. CLINICALTRIALSGOV IDENTIFIER: NCT00288626. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that participants with RRMS experienced sustained remissions with toxicities as expected from HDIT/HCT.
引用
- Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017. PMID: 28148635. doi:10.1212/WNL.0000000000003660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。